Skip to main content
AMA Journal of Ethics®
Illuminating the Art of Medicine

Main navigation

  • Issues
  • Articles
  • Cases
  • Art
  • Multimedia
  • CME
  • Topics
  • For Authors
  • Call for Papers
  • Call for Artwork
  • Call for Editorial Fellows
  • Art Collaborations
  • Register for Sep 10 Grand Rounds
  • En Español

Featured Content

Case and Commentary
Feb 2021

Fomento de la equidad en salud a través de un enfoque que evite los juicios de valor y contextualice la atención

Saul J. Weiner, MD

Cases

Topics
Core Competencies
Specialties
Language
Reset
  • cscm3-1910
    Case and Commentary
    Oct 2019

    How Should We Determine the Value of CAR T-Cell Therapy?

    Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
    “Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
    AMA J Ethics. 2019;21(10):E844-851. doi: 10.1001/amajethics.2019.844.
  • cscm2-1909
    Case and Commentary
    Sep 2019

    How Should Mission Trips Be Administered?

    Kristin K. Sznajder, PhD, MPH, Michael C. Chen, MD, and Dana Naughton, PhD, MSW
    With properly designed programs, universities can offer transformative benefits to patients, educators, and students.
    AMA J Ethics. 2019;21(9):E722-728. doi: 10.1001/amajethics.2019.722.
  • cscm3-1909
    Case and Commentary
    Sep 2019

    How Should We Decide Whether and When Some Care Is Better Than No Care?

    Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
    Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
    AMA J Ethics. 2019;21(9):E729-734. doi: 10.1001/amajethics.2019.729.
  • cscm4-1909
    Case and Commentary
    Sep 2019

    What Are Criteria for Considering Technologies’ Uses and Influences in LMICs’ Health Care Infrastructures?

    Rolvix Patterson and Richard Rohrer, MD
    Low-resource areas are heterogeneous and changing, so establishing an evidence base for decision making about technology use is an important priority.
    AMA J Ethics. 2019;21(9):E735-741. doi: 10.1001/amajethics.2019.735.
  • cscm1-1908
    Case and Commentary
    Aug 2019

    How Should Physicians Steward Limited Resources While Ensuring That Patients Can Access Needed Medicines?

    Pete Croughan and Rebekah E. Gee, MD, MPH
    Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients.
    AMA J Ethics. 2019;21(8):E630-635. doi: 10.1001/amajethics.2019.630.
  • cscm3-1907
    Case and Commentary
    Jul 2019

    Should Aggregate Patient Preference Data Be Used to Make Decisions on Behalf of Unrepresented Patients?

    Nathaniel Sharadin, PhD, MA
    Ethical and practical problems with preference modeling can undermine how reliably predictors can be used in high-stakes decisions.
    AMA J Ethics. 2019;21(7):E566-574. doi: 10.1001/amajethics.2019.566.
  • cscm2-1907
    Case and Commentary
    Jul 2019

    How Should Clinicians Navigate Decision Making for Unrepresented Patients?

    Timothy M. Dempsey, MD, MPH and Erin Sullivan DeMartino, MD
    A deliberative approach to responding to needs and vulnerabilities of unrepresented patients can help make the most of having too little information.
    AMA J Ethics. 2019;21(7):E559-565. doi: 10.1001/amajethics.2019.559.
  • cscm1-1907
    Case and Commentary
    Jul 2019

    When There’s No One to Whom an Error Can Be Disclosed, How Should an Error Be Handled?

    Ryan G. Chiu
    When a patient is incompetent and unrepresented, alternative strategies must be implemented to document and try to rectify an error.
    AMA J Ethics. 2019;21(7):E553-558. doi: 10.1001/amajethics.2019.553.
  • cscm4-1907
    Case and Commentary
    Jul 2019

    Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer?

    Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE
    Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients.
    AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
  • cscm3-1906
    Case and Commentary
    Jun 2019

    Does a Patient’s Trauma History Ethically Justify a Discriminatory Clinical Referral?

    John R. Stone, MD, PhD
    A “simplicity strategy” suggests expressing respect for persons and empathy and models inclusive group inquiry, epistemic humility, and justice.
    AMA J Ethics. 2019;21(6):E493-498. doi: 10.1001/amajethics.2019.493.

Pagination

  • First page « First
  • Previous page ‹ Prev
  • …
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Current page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • …
  • Next page Next ›
  • Last page Last »
AMA Journal of Ethics®
Illuminating the Art of Medicine

Footer menu

  • About
  • Conditions of Use
  • Privacy Policy
  • Website Accessibility
  • FAQ
  • Contact
American Medical Association

Email Signup


We do not share email addresses and will only use yours to send new content alerts. (Add [email protected] to your contacts to help ensure receipt.)
Copyright 2025 American Medical Association. All Rights Reserved. ISSN 2376-6980